Englewood Cliffs NJ, March 04, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has executed an exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as “Joint-homing peptides for use in the investigation and treatment of arthritogenic processes.


Previous articleRegulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research
Next articleTryp Therapeutics Announces Application to List on OTCQB